Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 1998

View Archived Issues

Focus on Sankyo's R&D activities at home and abroad

NeoTherapeutics completes enrollment in phase II trial of Neotrofin

Cel-Sci's AIDS vaccine demonstrates effectiveness in animal tests

Novartis submits NDA for Trileptal

Palatin Technologies initiates phase III clinical trials with LeuTech

New Zeneca facility to manufacture new cancer treatment

Bristol-Myers Squibb and Unilever enter collaborative agreement for hair loss research

HMR announces Spanish launch of Telfast

Vitronectin receptor antagonists from HMR particularly useful as bone resorption inhibitors

Meloxicam comes out ahead of NSAIDs in comparative studies evaluating tolerability

Endothelin antagonists for hypertension in development at Tanabe Seiyaku

HMR presents new bile acid uptake inhibitors for hyperlipidemic disorders

Hughes Institute scientists recognized for breakthrough discovery in AIDS prevention

New moenomycin salts for H. pylori-related disorders

European academic researchers disclose nonxanthine adenosine receptor antagonists

Sibrafiban interactions studied in canine model

SB receives clearance to market Seroxat for important new indication in the U.K.

Elan obtains North American marketing rights for frovatriptan

Low-dose xemilofiban + high-dose ASA provides protection in canine arterial thrombosis model

Creative BioMolecules receives NIH grant for Parkinson's disease research

Early clinical study results published for Organon antiprogestagen

Geranylgeranylacetone: mechanism of increased hexosamine production in RGM-1 cells

Myriad Genetics, Schering AG collaborate on new drug development

Does ofloxacin increase response rate to IFN-alpha in HCV?

FDA continues to support development of SciClone's CF Rx

Celgene initiates pivotal trials with d-MPH

Verelan and Verelan PM licensed to Schwarz for U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...